Date published: 2025-10-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

UBL4B Inhibitors

UBL4B inhibitors are chemical agents that target and impede the activity of the ubiquitin-like protein 4B (UBL4B), a member of the ubiquitin-like protein family. The inhibition process typically involves the molecular interaction between the inhibitor and specific sites on the UBL4B protein, which disrupts its natural function. This interaction can be competitive, non-competitive, or uncompetitive, depending on whether the inhibitor directly competes with the natural substrate or ligand of UBL4B, binds to a separate site to induce a conformational change, or interacts only when the protein is in a complex with its substrate, respectively. The design of UBL4B inhibitors is a sophisticated task that requires a comprehensive understanding of the protein's structure, the nature of its interaction with other cellular components, and the signaling pathways it is involved in. Advanced techniques such as molecular docking, virtual screening, and structure-activity relationship (SAR) studies are commonly employed to guide the chemical synthesis of these inhibitors, ensuring specificity and a high affinity for the UBL4B protein.

Within the realm of UBL4B inhibitors, structural diversity is vast, encompassing small organic molecules, peptides, and potentially larger biomolecule-based inhibitors. The molecular architecture of these inhibitors is critical, as it determines both the potency and selectivity of the inhibitor for the UBL4B protein. Researchers meticulously analyze the three-dimensional structure of UBL4B, taking into account factors such as the arrangement of amino acids in the active or binding sites, the protein's dynamic conformational states, and the potential for allosteric regulation. The interaction between UBL4B and its inhibitors is not merely a lock-and-key mechanism but often involves induced fit or conformational adaptations that allow for high-fidelity binding. The physicochemical properties of UBL4B inhibitors, such as solubility, stability, and the ability to traverse cellular membranes, are also pivotal considerations in their design.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Geldanamycin

30562-34-6sc-200617B
sc-200617C
sc-200617
sc-200617A
100 µg
500 µg
1 mg
5 mg
$38.00
$58.00
$102.00
$202.00
8
(1)

Geldanamycin binds to heat shock protein 90 (Hsp90) and inhibits its chaperone activity. Hsp90 is crucial for the stability and function of many client proteins, and by inhibiting Hsp90, UBL4B stability can be diminished.

Withaferin A

5119-48-2sc-200381
sc-200381A
sc-200381B
sc-200381C
1 mg
10 mg
100 mg
1 g
$127.00
$572.00
$4090.00
$20104.00
20
(1)

Withaferin A is a steroidal lactone that disrupts the cytoskeletal organization and induces the degradation of vimentin. Disruption of the cytoskeleton impairs cellular trafficking, potentially diminishing UBL4B function.

MG-132 [Z-Leu- Leu-Leu-CHO]

133407-82-6sc-201270
sc-201270A
sc-201270B
5 mg
25 mg
100 mg
$56.00
$260.00
$980.00
163
(3)

MG-132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins, leading to cellular stress and potential downregulation of UBL4B due to the perturbation in proteostasis.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$132.00
$1064.00
115
(2)

Bortezomib is another proteasome inhibitor with a mechanism similar to MG-132. By preventing the proteasomal breakdown of proteins, it may indirectly decrease UBL4B activity through proteostatic stress.

Cycloheximide

66-81-9sc-3508B
sc-3508
sc-3508A
100 mg
1 g
5 g
$40.00
$82.00
$256.00
127
(5)

Cycloheximide inhibits protein biosynthesis by interfering with the translocation step in protein synthesis, leading to reduced levels of newly synthesized proteins including UBL4B.

Tunicamycin

11089-65-9sc-3506A
sc-3506
5 mg
10 mg
$169.00
$299.00
66
(3)

Tunicamycin inhibits N-linked glycosylation. As glycosylation can affect protein folding and stability, this may indirectly affect UBL4B stability if it or its interacting proteins are glycosylated.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$62.00
$155.00
$320.00
233
(4)

Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway, which is involved in protein synthesis and autophagy. This inhibition could lead to diminished synthesis and altered degradation of UBL4B.

Chloroquine

54-05-7sc-507304
250 mg
$68.00
2
(0)

Chloroquine inhibits autophagy by preventing the acidification of lysosomes. This could result in altered protein degradation pathways, affecting the turnover and function of UBL4B.

Puromycin dihydrochloride

58-58-2sc-108071
sc-108071B
sc-108071C
sc-108071A
25 mg
250 mg
1 g
50 mg
$40.00
$210.00
$816.00
$65.00
394
(15)

Puromycin causes premature chain termination during protein synthesis, resulting in the production of truncated proteins. This action could lead to reduced levels of functional UBL4B.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$94.00
$349.00
114
(2)

Thapsigargin is a sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) pump inhibitor, leading to disruption of calcium homeostasis. Disrupted calcium signaling may indirectly decrease UBL4B function.